Pembrolizumab-Sacituzumab Govitecan Combination to Treat High-risk, Localized Bladder Cancer
Clinical trial NCT05535218 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05535218
- Sponsor
- Claudia Guerrieri
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-09-20
- Primary completion
- 2027-02-01
- Enrollment
- 48
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.